NASDAQ$TNYA
Tenaya Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Tenaya Therapeutics reported its Q4 and full year 2021 financial results, highlighting progress in research, preclinical development, manufacturing, and corporate operations. The company is advancing three therapeutic candidates towards clinical trials and strengthening its leadership team.
- TN-201 IND application expected to be submitted to the FDA in the second half of 2022.
- TN-301 IND application expected to be submitted to the FDA in the second half of 2022.
- TN-401 IND application expected to be submitted to the FDA in 2023.
- cGMP manufacturing facility expected to be operational in the first half of 2022.
Headline financials
Revenue & EPS history
Tenaya Therapeutics · Revenue · Quarterly
$225K
Forward guidance
Tenaya Therapeutics anticipates continued progress in advancing its therapeutic candidates towards clinical trials and strengthening its manufacturing and clinical development capabilities. The company expects its cash reserves to be sufficient to fund operations into the second half of 2023.
Tailwinds
- TN-201 IND application submission expected in the second half of 2022
- TN-301 IND application submission expected in the second half of 2022
- TN-401 IND application submission expected in 2023
- cGMP manufacturing facility expected to be operational in the first half of 2022
- Cash reserves expected to fund operations into the second half of 2023
Headwinds
- Risks associated with discovering, developing, and commercializing drugs
- Uncertainties regarding preclinical studies and clinical trials
- Potential impacts of the COVID-19 pandemic on manufacturing and operations
- Risk of clinical trial results differing from expectations
- Reliance on third parties
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2021
+2.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-5.6%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+39.8%
Q3 2022
Best reaction
-18.7%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +30.3% | -4.2% | |
| Q4 2025 | -1.3% | -0.2% | -19.7% | |
| Q3 2025 | -1.4% | -7.0% | -4.9% | |
| Q1 2025 | +7.8% | -3.3% | +38.2% | |
| Q4 2024 | -6.5% | -12.7% | -38.4% | |
| Q3 2024 | +17.4% | +20.7% | +68.1% | |
| Q1 2024 | -0.7% | +8.9% | -12.6% | |
| Q4 2023 | -8.9% | -5.1% | -13.6% | |
| Q3 2023 | -7.8% | -10.2% | -2.9% | |
| Q2 2023 | +7.3% | +0.0% | -24.6% | |
| Q1 2023 | +12.1% | +7.2% | +9.0% | |
| Q4 2022 | -18.7% | -20.6% | -25.9% | |
| Q3 2022 | +39.8% | +53.4% | +11.0% | |
| Q2 2022 | +1.5% | +6.5% | -11.3% | |
| Q1 2022 | -5.7% | -6.7% | -29.9% | |
| Q4 2021 | +6.0% | +3.2% | -5.0% | |
| Q3 2021 | +7.7% | -13.5% | -28.1% | |
| Q2 2021 | -2.8% | -12.6% | -6.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro